Patient-Reported Burden of Illness in a Prevalent COPD Population Treated with Long-Acting Muscarinic Antagonist Monotherapy: A Claims-Linked Patient Survey Study

Abstract

Introduction: Symptom burden in inadequately controlled chronic obstructive pulmonary disease (COPD) considerably impacts quality of life, healthcare resource utilization (HCRU) and associated costs. This claims-linked cross-sectional survey study assessed symptom burden and HCRU among a prevalent population of COPD patients prescribed long-acting muscarinic antagonist (LAMA) monotherapy. Methods: Patients were identified using claims data from the Optum Research Database. Eligible patients were aged C 40 years with 12 months' continuous enrollment in a US Enhanced digital features To view enhanced digital features for this article go to https://doi.org/10.6084/ m9.figshare.7819946.

Predictors of Symptom Burden in Patients with COPD on LAMA Monotherapy: Multivariable Analysis of a Claims-Linked Survey Study

“…The CAT has been found to be a reliable, appropriate, and responsive instrument for measuring symptom burden in patients with COPD [6,10,24,26,27], and has demonstrated good correlation with established QoL questionnaires, including the SGRQ, and other relevant measures of disease severity [28,29]. This is consistent with published data, where a high level of correlation between measures of COPD symptom burden was noted, with [ 70% of patients obtaining high scores on at least two PROs (Supplementary Table 1) [11].…”

“…The study was a multivariable analysis of a previously reported claims-linked, cross-sectional survey of patients with COPD who were enrolled in commercial or Medicare Advantage (MA) insurance plans and prescribed LAMA monotherapy (study 205862 [HO-16-16642]) [11]. Medical and pharmacy claims and enrollment data from the Optum Research Database (ORD) were used to identify patients between October 1, 2015 and September 30, 2016.…”

“…Eligible patients were at least 40 years of age with C 2 medical claims with COPD diagnosis codes (International Classification of Disease-10th Revision-Clinical Modification [ICD-10-CM] J40-J44 codes) in any position at least 30 days apart during the 12-month baseline period [11]. Participants were also required to be continuously enrolled in a commercial or MA health plan with both medical and pharmacy benefits during the baseline period and to have C 2 pharmacy claims for a LAMA monotherapy in the most recent 6 months of the baseline period [11]. Patients were excluded if they had evidence of prior use of any ICS-or LABA-containing therapy (ICS, ICS/LABA, and LAMA/LABA) during the baseline period.…”

“…As previously described, 2275 patients met the eligibility criteria and were invited to participate in the study, of whom 528 completed the survey. The response rate was 29.8%; [13] the final evaluable sample included 433 patients on LAMA monotherapy with matched claims, survey, and diary data [11]. Patient demographic, sociodemographic, and clinical characteristics are presented in Table 1.…”

“…The objective of this multivariable analysis of a previously reported claims-linked, crosssectional survey study [11] was to determine demographic, sociodemographic, and clinical characteristics that are predictors of higher symptom burden (as measured by the CAT), in an insured US population of patients with COPD receiving treatment with LAMA monotherapy.…”